

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *				2. I	2. Issuer Name and Ticker or Trading Symbol							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Weinberg Uri				No	NovoCure Ltd [NVCR]									,			
(Last)	(Last) (First) (Middle)				3. Date of Earliest Transaction (MM/DD/YYYY)							Director 10% Owner X Officer (give title below) Other (specify below)					
C/O NOVOCURE INC.,, 20 VALLEY STREAM PARKWAY, SUITE 300					3/2/2021								Chief Science	Officer			
·				4. I	4. If Amendment, Date Original Filed (MM/DD/YYYY)							6. Individual or Joint/Group Filing (Check Applicable Line)					
MALVERN, PA 19355 (City) (State) (Zip)													_X _ Form filed by One Reporting Person Form filed by More than One Reporting Person				
			Table I -	- Non-Der	ivat	tive Secu	rities Ac	quire	ed, D	isposed	of, o	or Be	neficially Owne	d			
1.Title of Security (Instr. 3)			2.			2A. Deemed Execution Date, if any 3. Trans (Instr. 8		or Dis		curities Acquired (A) sposed of (D) . 3, 4 and 5)		I	(Instr. 3 and 4) Form: Direct (I		Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	V	Amo	_ `) 1	Price				(I) (Instr. 4)	(msu: 1)
Restricted Share Units 3/2/202				3/2/2021	A 8709 (1) A 80 36306			D									
	Tal	ole II - Dei	rivative S	Securities :	Ben	eficially	Owned	(e.g.,	puts	, calls, v	varra	ants,	options, conver	tible secu	ırities)		
(Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deeme Execution Date, if an		5. Number Derivative Acquired (Disposed ((Instr. 3, 4		Securities A) or of (D)	Date Exercisable an Expiration Date		7. Title and Securities I Derivative (Instr. 3 and		Underlying Security	Derivative Security (Instr. 5)	Securities Beneficially Owned	Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exerci	isable	Expiration Date	n Title	le	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)	
Options to Buy Ordinary Shares	\$153.09	3/2/2021		A		16003		<u>(2</u>	<u>2)</u>	3/1/2031		rdinary Shares	16003.0	\$0	16003	D	

Explanation of Responses:

- (1) Represents restricted share units that are scheduled to vest in equal installments on each of March 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.
- (2) Options to buy 16,003 ordinary shares will vest and become exercisable in equal installments on each of March 2, 2022, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.

Reporting Owners

D	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Weinberg Uri C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN, PA 19355			Chief Science Officer					

Signatures

By: /s/ Steven Robbins, Attorney in Fact for Uri Weinberg 3/4/2021

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

